Meyer Helmut E, Stühler Kai
Medizinisches Proteom-Center, Ruhr-University Bochum, Bochum, Germany.
Proteomics. 2007 Sep;7 Suppl 1:18-26. doi: 10.1002/pmic.200700183.
Biomarkers allowing early detection of disease or therapy control have a huge influence in curing a disease. A wide variety of methods were applied to find new biomarkers. In contrast to methods focused on DNA or mRNA techniques, approaches considering proteins as potential biomarker candidates have the advantage that proteins are more diverse than DNA or RNA and are more reflective of a biological system. Here, we present an approach for the identification of new biomarkers relying on our experience from the past 10 years of proteomics, outlining a concept of "high-performance proteomics" This approach is based on quantitative proteome analysis using a sufficient number of clinical samples and statistical validation of proteomics data by independent methods, such as Western blot analysis or immunohistochemistry.
能够实现疾病早期检测或治疗监控的生物标志物对疾病的治愈具有重大影响。人们应用了各种各样的方法来寻找新的生物标志物。与专注于DNA或mRNA技术的方法不同,将蛋白质视为潜在生物标志物候选物的方法具有这样的优势,即蛋白质比DNA或RNA更加多样,并且更能反映生物系统。在此,我们基于过去十年蛋白质组学的经验,提出一种鉴定新生物标志物的方法,概述了“高性能蛋白质组学”的概念。这种方法基于使用足够数量的临床样本进行定量蛋白质组分析,并通过蛋白质印迹分析或免疫组织化学等独立方法对蛋白质组学数据进行统计验证。